Cargando…
Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing/remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923173/ https://www.ncbi.nlm.nih.gov/pubmed/33669799 http://dx.doi.org/10.3390/jcm10040868 |
_version_ | 1783658853374623744 |
---|---|
author | Kapica-Topczewska, Katarzyna Collin, François Tarasiuk, Joanna Czarnowska, Agata Chorąży, Monika Mirończuk, Anna Kochanowicz, Jan Kułakowska, Alina |
author_facet | Kapica-Topczewska, Katarzyna Collin, François Tarasiuk, Joanna Czarnowska, Agata Chorąży, Monika Mirończuk, Anna Kochanowicz, Jan Kułakowska, Alina |
author_sort | Kapica-Topczewska, Katarzyna |
collection | PubMed |
description | The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing/remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and progression independent of relapses and brain MRI Activity (PIRMA). Data from the Therapeutic Program Monitoring System were analyzed. Three panels of patients were identified: R0, no relapse during treatment, and R1 and R2 with the occurrence of relapse during the first and the second year of treatment, respectively. In the R0 panel, we detected 4.6% PIRA patients at 24 months (p < 0.001, 5.0% at 36 months, 5.6% at 48 months, 6.1% at 60 months). When restricting this panel to patients without brain MRI activity, we detected 3.0% PIRMA patients at 12 months, 4.5% at 24 months, and varying from 5.3% to 6.2% between 36 and 60 months of treatment, respectively. In the R1 panel, RAW was detected in 15.6% patients at 12 months and, in the absence of further relapses, 9.7% at 24 months and 6.8% at 36 months of treatment. The R2 group was associated with RAW significantly more frequently at 24 months compared to the R1 at 12 months (20.7%; p < 0.05), but without a statistical difference later on. In our work, we confirmed that disability progression was independent of relapses and brain MRI activity. |
format | Online Article Text |
id | pubmed-7923173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79231732021-03-03 Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland Kapica-Topczewska, Katarzyna Collin, François Tarasiuk, Joanna Czarnowska, Agata Chorąży, Monika Mirończuk, Anna Kochanowicz, Jan Kułakowska, Alina J Clin Med Article The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing/remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and progression independent of relapses and brain MRI Activity (PIRMA). Data from the Therapeutic Program Monitoring System were analyzed. Three panels of patients were identified: R0, no relapse during treatment, and R1 and R2 with the occurrence of relapse during the first and the second year of treatment, respectively. In the R0 panel, we detected 4.6% PIRA patients at 24 months (p < 0.001, 5.0% at 36 months, 5.6% at 48 months, 6.1% at 60 months). When restricting this panel to patients without brain MRI activity, we detected 3.0% PIRMA patients at 12 months, 4.5% at 24 months, and varying from 5.3% to 6.2% between 36 and 60 months of treatment, respectively. In the R1 panel, RAW was detected in 15.6% patients at 12 months and, in the absence of further relapses, 9.7% at 24 months and 6.8% at 36 months of treatment. The R2 group was associated with RAW significantly more frequently at 24 months compared to the R1 at 12 months (20.7%; p < 0.05), but without a statistical difference later on. In our work, we confirmed that disability progression was independent of relapses and brain MRI activity. MDPI 2021-02-19 /pmc/articles/PMC7923173/ /pubmed/33669799 http://dx.doi.org/10.3390/jcm10040868 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kapica-Topczewska, Katarzyna Collin, François Tarasiuk, Joanna Czarnowska, Agata Chorąży, Monika Mirończuk, Anna Kochanowicz, Jan Kułakowska, Alina Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland |
title | Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland |
title_full | Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland |
title_fullStr | Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland |
title_full_unstemmed | Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland |
title_short | Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland |
title_sort | assessment of disability progression independent of relapse and brain mri activity in patients with multiple sclerosis in poland |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923173/ https://www.ncbi.nlm.nih.gov/pubmed/33669799 http://dx.doi.org/10.3390/jcm10040868 |
work_keys_str_mv | AT kapicatopczewskakatarzyna assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland AT collinfrancois assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland AT tarasiukjoanna assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland AT czarnowskaagata assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland AT chorazymonika assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland AT mironczukanna assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland AT kochanowiczjan assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland AT kułakowskaalina assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland |